Lyell Immunopharma (LYEL) Cash & Equivalents (2019 - 2026)

Lyell Immunopharma's Cash & Equivalents history runs 8 years deep, the most recent figure standing at $90.8 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 24.56% year-over-year to $90.8 million; the TTM figure through Mar 2026 stood at $90.8 million (down 24.56% YoY), while the FY2025 annual figure was $60.2 million, down 43.01% from the prior year.
• Cash & Equivalents came in at $90.8 million for Q1 2026 at Lyell Immunopharma, up from $60.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $286.2 million in Q3 2023 to a low of $60.2 million in Q4 2025.
• A 5-year average of $140.7 million and a median of $123.6 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slumped 70.44% in 2022 and surged 146.08% in 2023, its largest moves.
• Lyell Immunopharma's Cash & Equivalents stood at $123.6 million in 2022, then increased by 17.88% to $145.6 million in 2023, then slipped by 27.5% to $105.6 million in 2024, then sank by 43.01% to $60.2 million in 2025, then surged by 50.83% to $90.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $90.8 million, $60.2 million, and $123.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison